Pediatric Tuberculosis Treatment Guidelines

Standard Treatment Regimen

The American Thoracic Society recommends a treatment regimen consisting of rifampin and isoniazid for 6 months, supplemented by pyrazinamide for the first 2 months, with ethambutol included in the initial regimen until drug susceptibility results are available 1, 2
The standard treatment for pulmonary TB in children includes isoniazid: 10-15 mg/kg/day, rifampin: 10-20 mg/kg/day, pyrazinamide: 15-30 mg/kg/day, and ethambutol: 15-25 mg/kg/day 1, 2, 3

For TB meningitis, treatment should be extended to 12 months total, with an initial 2 months of rifampin, isoniazid, pyrazinamide, and a fourth drug, followed by rifampin and isoniazid for 10 additional months 1, 4
The American Academy of Pediatrics recommends adjunctive corticosteroids for moderate to severe TB meningitis 1, 4
For disseminated/miliary TB, a six-month regimen is recommended unless there is CNS involvement, in which case treatment should be extended to 12 months 1, 4

The American Thoracic Society recommends dosages be rounded up to facilitate administration of appropriate volumes of syrup or tablet strengths, and recalculation of dosages with weight gain 1
Supplemental pyridoxine is recommended for breast-fed infants, malnourished children, and HIV-infected children 1, 3

For isoniazid-resistant TB, treatment with rifampin, pyrazinamide, and ethambutol for 6-12 months is recommended, with a fluoroquinolone added for extensive disease 3
For rifampin-resistant TB, treatment with isoniazid, pyrazinamide, ethambutol, and a fluoroquinolone for 12-15 months is recommended, with an injectable agent added for the first few months in cases of extensive disease 3
For MDR-TB, an individualized regimen based on susceptibility testing is recommended, with treatment typically lasting 18-24 months 3

Directly observed therapy (DOT) is strongly recommended to ensure adherence, as recommended by the Infectious Diseases Society of America 2

Inadequate duration of therapy, especially for extrapulmonary TB, which requires longer treatment than pulmonary TB, as noted by the American Academy of Pediatrics 1, 4
The American Academy of Pediatrics recommends including ethambutol as part of the initial regimen for children with TB, even though there are concerns about monitoring visual acuity in young children 2

The American Thoracic Society recommends that when drug resistance is suspected, ethambutol should be included in the initial regimen until drug susceptibility testing confirms the organism is fully susceptible, unless there is minimal possibility of drug resistance 5
For suspected drug-resistant TB, the Centers for Disease Control and Prevention suggests using individualized regimens based on susceptibility testing, typically 18-24 months duration for MDR-TB, and discussing all drug-resistant cases at a TB consilium 6

The American Academy of Pediatrics recommends using directly observed therapy (DOT) when treating children with TB to ensure adherence, given the 6-month minimum duration and complexity of multi-drug regimens 5

The World Health Organization recommends obtaining bacteriologic cultures before starting therapy to confirm susceptibility, and assessing for HIV co-infection, as these children may require longer treatment courses 5
The Centers for Disease Control and Prevention suggests monitoring for adverse drug reactions using active drug safety monitoring during treatment 6